Drug Trial Radar · NCT02676089
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,437
Actual
Start
Apr 6, 2016
Primary completion
May 28, 2018
Study completion May 28, 2018
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) in patients with uncontrolled asthma under medium doses of inhaled corticosteroid/long-acting β2-adrenergic receptor agonists (ICS/LABA), in patients with uncontrolled asthma who received medium doses of ICS/LABA. The treatments tested the improvement of the forced expiratory volume in the 1st second (FEV1) and the reduction of moderate and severe asthma exacerbations rate.
Conditions
- Asthma
Interventions
CHF 5993 200/6/12.5 µgDrug
CHF 1535 200/6 µgDrug
CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26Time frame: Week 0 (pre-treatment, baseline) to Week 26.
- 2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment PeriodTime frame: Week 0 (pre-treatment, baseline) to Week 52.
Locations
244 sites in 17 countries. Site status is shown where the registry gives one.
Chiesi Clinical Trial Site 432702
Buenos Aires, Argentina
Chiesi Clinical Trial Site 432704
CABA, Argentina
Chiesi Clinical Trial Site 432705
Mar del Plata, Argentina
Chiesi Clinical Trial Site 432701
Quilmes, Argentina
Chiesi Clinical Trial Site 432703
San Miguel de Tucumán, Argentina
Chiesi Clinical Trial Site 432706
San Miguel de Tucumán, Argentina
Chiesi Clinical Trial Site 112703
Homyel, Belarus
Chiesi Clinical Trial Site 112704
Homyel, Belarus
Chiesi Clinical Trial Site 112701
Minsk, Belarus
Chiesi Clinical Trial Site 112702
Minsk, Belarus
Chiesi Clinical Trial Site 112705
Minsk, Belarus
Chiesi Clinical Trial Site 100707
Blagoevgrad, Bulgaria
Chiesi Clinical Trial Site 100720
Burgas, Bulgaria
Chiesi Clinical Trial Site 100718
Gabrovo, Bulgaria
Chiesi Clinical Trial Site 100713
Haskovo, Bulgaria
Chiesi Clinical Trial Site 100722
Montana, Bulgaria
Chiesi Clinical Trial Site 100702
Pleven, Bulgaria
Chiesi Clinical Trial Site 100705
Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100708
Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100715
Plovdiv, Bulgaria
Chiesi Clinical Trial Site 100716
Rousse, Bulgaria
Chiesi Clinical Trial Site 100701
Sofia, Bulgaria
Chiesi Clinical Trial Site 100703
Sofia, Bulgaria
Chiesi Clinical Trial Site 100704
Sofia, Bulgaria
Chiesi Clinical Trial Site 100709
Sofia, Bulgaria
Chiesi Clinical Trial Site 100719
Sofia, Bulgaria
Chiesi Clinical Trial Site 100706
Stara Zagora, Bulgaria
Chiesi Clinical Trial Site 100712
Stara Zagora, Bulgaria
Chiesi Clinical Trial Site 100710
Varna, Bulgaria
Chiesi Clinical Trial Site 100711
Vidin, Bulgaria
Chiesi Clinical Trial Site 100721
Vidin, Bulgaria
Chiesi Clinical Trial Site 203711
Blansko, Czechia
Chiesi Clinical Trial Site 203702
Brandýs nad Labem, Czechia
Chiesi Clinical Trial Site 203708
Brno, Czechia
Chiesi Clinical Trial Site 203707
Jindřichův Hradec, Czechia
Chiesi Clinical Trial Site 203705
Kralupy nad Vltavou, Czechia
Chiesi Clinical Trial Site 203709
Miroslav, Czechia
Chiesi Clinical Trial Site 203704
Opava, Czechia
Chiesi Clinical Trial Site 203701
Prague, Czechia
Chiesi Clinical Trial Site 203703
Prague, Czechia
Showing 40 of 244 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.